0001193125-21-149030.txt : 20210504 0001193125-21-149030.hdr.sgml : 20210504 20210504075401 ACCESSION NUMBER: 0001193125-21-149030 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 14 CONFORMED PERIOD OF REPORT: 20210504 ITEM INFORMATION: Results of Operations and Financial Condition ITEM INFORMATION: Financial Statements and Exhibits FILED AS OF DATE: 20210504 DATE AS OF CHANGE: 20210504 FILER: COMPANY DATA: COMPANY CONFORMED NAME: REPLIGEN CORP CENTRAL INDEX KEY: 0000730272 STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836] IRS NUMBER: 042729386 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 000-14656 FILM NUMBER: 21886040 BUSINESS ADDRESS: STREET 1: 41 SEYON STREET STREET 2: BUILDING 1, SUITE 100 CITY: WALTHAM STATE: MA ZIP: 02453 BUSINESS PHONE: 7814499560 MAIL ADDRESS: STREET 1: 41 SEYON STREET STREET 2: BUILDING 1, SUITE 100 CITY: WALTHAM STATE: MA ZIP: 02453 8-K 1 d227347d8k.htm 8-K 8-K
REPLIGEN CORP false 0000730272 0000730272 2021-05-04 2021-05-04

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

 

FORM 8-K

 

 

CURRENT REPORT

Pursuant to Section 13 or 15(d)

of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): May 4, 2021

 

 

REPLIGEN CORPORATION

(Exact name of registrant as specified in its charter)

 

 

 

Delaware   001-14656   04-2729386

(State or other jurisdiction

of incorporation)

 

(Commission

File Number)

 

(I.R.S. Employer

Identification No.)

41 Seyon Street, Bldg. 1, Suite 100, Waltham, MA 02453

(Address of principal executive offices, including zip code)

(781) 250-0111

(Registrant’s telephone number, including area code)

(Former Name or Former Address, if Changed Since Last Report)

 

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

 

Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

 

Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

 

Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

 

Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

 

Title of each class

 

Trading

Symbol(s)

 

Name of each exchange

on which registered

Common Stock, par value $0.01 per share   RGEN   The Nasdaq Global Select Market

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).

Emerging growth company

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

 

 

 


Item 2.02.

Results of Operations and Financial Condition.

On May 4, 2021, Repligen Corporation announced its financial results for the first quarter ended March 31, 2021. The full text of the press release issued in connection with the announcement is attached as Exhibit 99.1 to this Current Report on Form 8-K.

The information in this Form 8-K and the exhibit attached hereto shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific reference in such a filing.

 

Item 9.01.

Financial Statements and Exhibits.

(d) Exhibits

 

99.1    Press Release by Repligen Corporation, dated May 4, 2021
104    Cover page from this Current Report on Form 8-K, formatted in Inline XBRL


SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

    REPLIGEN CORPORATION
Date: May 4, 2021     By:  

/s/ Tony J. Hunt

      Tony J. Hunt
      President and Chief Executive Officer
EX-99.1 2 d227347dex991.htm EX-99.1 EX-99.1

Exhibit 99.1

 

LOGO

 

Repligen Corporation

41 Seyon Street

 

Building #1, Suite 100

 

Waltham, Massachusetts 02453

 

 

 

Repligen Reports First Quarter 2021 Financial Results

and Updates Full Year 2021 Financial Guidance

 

  -

Reported revenue was $142.8 million for the quarter, representing year-over-year growth of 88% and organic growth of 69%

 

  -

Growth driven by combination of COVID-related demand, base business strength and acquisition revenue

WALTHAM, Mass. – May 4, 2021 — Repligen Corporation (NASDAQ:RGEN), a life sciences company focused on bioprocessing technology leadership, today reported financial results for its first quarter ended March 31, 2021. Provided in this press release are financial highlights for the quarter, updates to our financial guidance for the year 2021, and access information for today’s webcast and conference call.

Tony J. Hunt, President and Chief Executive Officer said, “I am extremely proud of the way our team executed here in the first quarter. With unprecedented demand driven by strong COVID tailwinds, our whole team pivoted to deliver an impressive quarter with 88% growth and 69% organic. COVID revenue contribution ticked up to 25% of revenues in the first quarter and equally impressive was the performance of our non-COVID base business which was up 31% year-on-year. This is an endorsement of the differentiation we have in the marketplace with our technologies and the focus and execution of our global team. With accelerating orders, new product launches, planned new capacity and impressive growth across all four franchises, we are confident about the full year outlook for the Company and are updating our financial guidance to reflect our expectations for operating margin expansion and for organic revenue growth in the range of 42%-49%.”

First Quarter 2021 Highlights

 

   

Revenue increased by 88% year-over-year as reported and 69% organically, to $142.8 million

o COVID contributed 46 points, or 53% of revenue growth

o Base business (excluding COVID) contributed 27 points, or 31% of revenue growth

o Acquisitions made in 2020 contributed 14 points, or 16% of revenue growth

 

   

GAAP operating margin was 25.5%, an increase of 980 bps

 

   

Adjusted (non-GAAP) operating margin was 32.0%, an increase of 790 bps

 

   

GAAP fully diluted EPS was $0.52 compared to $0.18 for the first quarter of 2020

 

   

Adjusted (non-GAAP) fully diluted EPS increased to $0.68 compared to $0.32 for the first quarter of 2020

 

 

1


Financial Details for the First Quarter 2021

REVENUE

 

   

Total revenue for the first quarter of 2021 increased to $142.8 million compared to $76.1 million for the first quarter of 2020, a year-over-year gain of 88% as reported and 83% at constant currency, with organic growth of 69%.

GROSS PROFIT and GROSS MARGIN

 

   

Gross profit (GAAP) for the first quarter of 2021 was $83.1 million, a year-over-year increase of $39.0 million. Adjusted gross profit (non-GAAP) for the first quarter of 2021 was $84.8 million, a year-over-year increase of $40.3 million, or 90%.

 

   

Gross margin (GAAP) for the first quarter of 2021 was 58.2%, compared to 58.0% for the first quarter of 2020. Adjusted gross margin (non-GAAP) for the first quarter was 59.3%, compared to 58.5% in the 2020 period.

OPERATING INCOME

 

   

Operating income (GAAP) for the first quarter of 2021 was $36.4 million, a year-over-year increase of $24.5 million. Adjusted operating income (non-GAAP) for the first quarter of 2021 was $45.7 million, a year-over-year increase of $27.4 million or 149%.

 

   

Operating margin (GAAP) was 25.5% for the first quarter of 2021, compared to 15.6% for the first quarter of 2020. Adjusted operating margin (non-GAAP) for the first quarter was 32.0%, compared to 24.1% in the 2020 period.

NET INCOME

 

   

Net income (GAAP) for the first quarter of 2021 was $29.5 million compared to $9.8 million for the first quarter of 2020.

 

   

Adjusted net income (non-GAAP) for the first quarter of 2021 was $38.8 million, a year-over-year increase of $22.0 million or 131%.

EARNINGS PER SHARE

 

   

Earnings per share (GAAP) for the first quarter of 2021 were $0.52 on a fully diluted basis, compared to $0.18 for the first quarter of 2020.

 

   

Adjusted EPS (non-GAAP) for the first quarter of 2021 increased to $0.68 on a fully diluted basis, compared to $0.32 for the 2020 period.

EBITDA

 

   

EBITDA, a non-GAAP financial measure, for the first quarter of 2021 was $44.6 million compared to $18.7 million for the first quarter of 2020.

 

   

Adjusted EBITDA for the first quarter of 2021 was $48.8 million, a year-over-year increase of $27.5 million or 130%.

CASH

 

   

Our cash and cash equivalents at March 31, 2021 were $711.3 million, compared to $717.3 million at December 31, 2020.

 

2


All reconciliations of GAAP to adjusted (non-GAAP) figures above, as well as EBITDA to adjusted EBITDA, are detailed in the reconciliation tables included later in this press release.

Financial Guidance for 2021

Our financial guidance for the fiscal year 2021 is based on expectations for our existing business and includes the financial impact of our 2020 acquisitions of ARTeSYN Biosolutions Holdings Ireland Limited (which closed on December 3, 2020), Non-Metallic Solutions, Inc. (which closed on October 20, 2020 ) and Engineered Molding Technologies LLC (which closed on July 13, 2020). The guidance below excludes the impact of potential additional acquisitions and future fluctuations in foreign currency exchange rates.

FISCAL YEAR 2021 GUIDANCE:

 

   

Total revenue is expected to be in the range of $565-$590 million, an increase from our previous guidance of $500-$525 million. We expect overall revenue growth of 54%-61% and 52%-59% at constant currency. Organic growth is expected to be in the range of 42%-49%, an increase from our previous guidance of 26%-33%.

 

   

Revenue from COVID-related programs is expected to be in the range of $140-$160 million, an increase from our previous guidance of $90-$100 million. This represents incremental COVID-related revenue of $94-$114 million compared to 2020, representing 26-31 points of overall revenue growth.

 

   

Our expectations for incremental revenue related to acquisitions made in 2020 is unchanged, in the range of $37-$40 million and representing 10-11 points of overall revenue growth.

 

   

Gross margin is expected to be 57%-58% on both a GAAP and non-GAAP basis.

 

   

Income from operations is expected to be in the range of $127-$133 million on a GAAP basis, an increase from our previous guidance of $103-$109 million. Adjusted (non-GAAP) income from operations is expected to be in the range of $156-$162 million, an increase from our previous guidance of $134-$140 million.

 

   

Net income is expected to be in the range of $95-$99 million on a GAAP basis, an increase from our previous guidance of $74-$79 million. Adjusted (non-GAAP) net income is expected to be in the range of $126-$130 million, an increase from our previous guidance of $106-$111 million. Our current guidance reflects a tax rate of 19% on adjusted pre-tax income.

 

   

Fully diluted GAAP EPS is expected to be in the range of $1.67-$1.74, an increase from our previous guidance of $1.30-$1.38. Adjusted (non-GAAP) fully diluted EPS is expected to be in the range of $2.21-$2.28, an increase from our previous guidance of $1.86-$1.94.

 

3


Our non-GAAP guidance for the fiscal year 2021 excludes the following items:

 

   

$6.5 million estimated acquisition and integration expenses; $0.3 million in cost of product revenue, $1.1 million in research and development (R&D) and $5.1 million in selling, general and administrative expenses (SG&A).

 

   

$20.7 million estimated intangible amortization expense in SG&A.

 

   

Expected inventory step-up charges of $1.8 million related to 2020 acquisitions.

 

   

$11.1 million of non-cash interest expense (Other income (expense)) related to our convertible debt notes.

Our non-GAAP guidance for the fiscal year 2021 includes:

 

   

An income tax increase of $9.3 million, representing the tax impact of acquisition and integration costs, inventory step-up changes, intangible amortization and non-cash interest.

All reconciliations of GAAP to adjusted (non-GAAP) guidance are detailed in the tables included later in this press release.

Conference Call

Repligen will host a conference call and webcast today, May 4, 2021, at 8:30 a.m. EST, to discuss first quarter financial results and corporate developments. The conference call will be accessible by dialing toll-free (844) 274-3999 for domestic callers or (412) 317-5607 for international callers. No passcode is required for the live call. In addition, a webcast will be accessible via the Investor Relations section of the Company’s website. Both the conference call and webcast will be archived for a period of time following the live event. The replay dial-in numbers are (877) 344-7529 from the U.S., (855) 669-9658 from Canada and (412) 317-0088 for international callers. Replay listeners must provide the passcode 10155233.

Non-GAAP Measures of Financial Performance

To supplement our financial statements, which are presented on the basis of U.S. generally accepted accounting principles (GAAP), the following non-GAAP measures of financial performance are included in this release: revenue growth rate at constant currency, adjusted gross profit and adjusted gross margin, adjusted income from operations and adjusted operating margin, earnings before interest, taxes, depreciation and amortization (EBITDA), adjusted EBITDA, adjusted net income, adjusted net income per share, adjusted earnings per diluted share (EPS), adjusted cost of sales, adjusted R&D expense, adjusted SG&A, adjusted income tax expense and adjusted income tax rate. The Company provides organic revenue growth rates in constant currency to exclude the impact of both foreign currency translation, and the impact of acquisition revenue for current year periods that have no prior year comparable, in order to facilitate a comparison of its current revenue performance to its past revenue performance. The Company provides revenue growth rates in constant currency in order to facilitate a comparison of its current revenue performance to its past revenue performance. To calculate revenue growth rates in constant currency, the Company converts actual net sales from local currency to U.S. dollars using constant foreign currency exchange rates in the current and prior period.

 

4


The Company’s non-GAAP financial results and/or non-GAAP guidance exclude the impact of: acquisition and integration costs, inventory step-up charges and intangible amortization costs related to the Company’s acquisitions, as well as non-cash interest expenses and loss on conversion of debt related to the Company’s convertible debt, and the related impact on tax of non-GAAP charges. These costs are excluded because management believes that such expenses do not have a direct correlation to future business operations, nor do the resulting charges recorded accurately reflect the performance of our ongoing operations for the period in which such charges are recorded.

A reconciliation of GAAP to adjusted non-GAAP financial measures is included as an attachment to this press release. When analyzing the Company’s operating performance and guidance investors should not consider non-GAAP measures as substitutable for the comparable financial measures prepared in accordance with GAAP.

About Repligen Corporation

Repligen Corporation is a global life sciences company that develops and commercializes highly innovative bioprocessing technologies and systems that increase efficiencies in the process of manufacturing biological drugs. Our primary customers are biopharmaceutical drug developers and contract development and manufacturing organizations (CDMOs) worldwide. Our corporate headquarters are located in Waltham, Massachusetts, with additional administrative and manufacturing operations worldwide. The majority of our manufacturing sites are located within the U.S. (California, Massachusetts, New Jersey and New York), and outside of the U.S. we have sites in Estonia, Germany, Ireland, the Netherlands and Sweden.

The following constitutes a “Safe Harbor” statement under the Private Securities Litigation Reform Act of 1995: This press release contains forward-looking statements, which are made pursuant to the safe harbor provisions of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. Investors are cautioned that statements in this press release which are not strictly historical statements, including, without limitation, express or implied statements or guidance regarding current or future financial performance and position, including cash and investment position, demand in the markets in which we operate, the expected performance of our business, the expected performance of the Engineered Molding Technology, Non-Metallic Solutions and ARTeSYN Biosolutions businesses, the expected performance and success of our strategic partnerships, management’s strategy, plans and objectives for future operations or acquisitions, product development and sales, selling, general and administrative expenditures, intellectual property, development and manufacturing plans, availability of materials and product and adequacy of capital resources, our financing plans, and the projected impact of, and response to, the COVID-19 coronavirus pandemic on our business and on the U.S. and global economies constitute forward-looking statements identified by words like “believe,” “expect,” “may,” “will,” “should,” “seek,” “anticipate,” “projected,” “estimated,” “planned,” or “could” and similar expressions. Forward-looking statements are neither historical facts nor assurances of future performance. Because forward-looking statements relate to the future, they are subject to a number of risks and uncertainties that could cause actual results to differ materially from those anticipated, including, without limitation, risks associated with the following: the effect of the COVID-19 coronavirus pandemic, including mitigation efforts and economic effects, on our business operations and the operations of our customers and suppliers; the ultimate impact of the COVID-19 coronavirus pandemic on our business or financial results; our ability to successfully grow our bioprocessing business, including as a result of acquisition, commercialization or partnership opportunities; our ability to successfully integrate any acquisitions, our ability to develop and commercialize products and the market acceptance of our products; our ability to integrate the Engineered Molding Technology, Non-Metallic Solutions and ARTeSYN Biosolutions businesses successfully into our business and achieve the expected benefits of the acquisitions; reduced demand for our products that adversely

 

5


impacts our future revenues, cash flows, results of operations and financial condition; our ability to compete with larger, better financed bioprocessing, pharmaceutical and biotechnology companies; our compliance with all U.S. Food and Drug Administration and EMEA regulations; our volatile stock price; and other risks detailed in Repligen’s Annual Report on Form 10-K for the year ended December 31, 2020 and the most recently filed Quarterly Report on Form-10-Q on file with the Securities and Exchange Commission and the other reports that Repligen periodically files with the Securities and Exchange Commission. Actual results may differ materially from those Repligen contemplated by these forward-looking statements. Therefore, you should not rely on any of these forward-looking statements. These forward-looking statements reflect management’s current views, expectations and assumptions regarding the future of our business, future plans and strategies, projections, anticipated events and trends, the economy and other future conditions, and is based on only on information currently available to us. Repligen does not undertake to update, whether written or oral, any of these forward-looking statements to reflect a change in its views or events or circumstances, whether as a result of new information, future development or otherwise, that occur after the date hereof except as required by law.

Repligen Contact:

Sondra S. Newman

Global Head of Investor Relations

(781) 419-1881

investors@repligen.com

 

6


REPLIGEN CORPORATION

CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS

(Unaudited, amounts in thousands, except share and per share data)

 

     Three Months Ended
March 31,
 
     2021     2020  

Revenue:

    

Product revenue

   $ 142,737     $ 76,060  

Royalty and other revenue

     100       30  
  

 

 

   

 

 

 

Total revenue

     142,837       76,090  

Costs and expenses:

    

Cost of product revenue

     59,747       31,982  

Research and development

     7,612       4,702  

Selling, general and administrative

     39,095       27,500  
  

 

 

   

 

 

 
     106,454     64,184  
  

 

 

   

 

 

 

Income from operations

     36,383       11,906  

Investment income

     52       1,364  

Interest expense

     (3,106     (2,976

Other (expenses) income, net

     (224     382  
  

 

 

   

 

 

 

Income before income taxes

     33,105       10,676  

Income tax provision

     3,655       861  
  

 

 

   

 

 

 

Net income

   $ 29,450     $ 9,815  
  

 

 

   

 

 

 

Earnings per share:

    

Basic

   $ 0.54     $ 0.19  
  

 

 

   

 

 

 

Diluted

   $ 0.52     $ 0.18  
  

 

 

   

 

 

 

Weighted average shares outstanding:

    

Basic

     54,805,051       52,138,673  
  

 

 

   

 

 

 

Diluted

     56,868,793       53,108,847  
  

 

 

   

 

 

 

 

                                             
Balance Sheet Data:    March 31,
2021
     December 31,
2020
 

Cash, cash equivalents and marketable securities

   $ 711,318      $ 717,292  

Working capital

     613,007        583,426  

Total assets

     1,927,327        1,902,887  

Long-term obligations

     57,783        54,781  

Accumulated earnings

     95,219        65,769  

Stockholders’ equity

     1,556,216        1,529,150  

 

7


REPLIGEN CORPORATION

RECONCILIATION OF GAAP INCOME FROM OPERATIONS TO

NON-GAAP (ADJUSTED) INCOME FROM OPERATIONS

(Unaudited, amounts in thousands)

 

     Three Months Ended
March 31,
 
     2021      2020  

GAAP INCOME FROM OPERATIONS

   $ 36,383      $ 11,906  

ADJUSTMENTS TO INCOME FROM OPERATIONS:

     

Inventory step-up charges

     1,598        —    

Acquisition and integration costs

     2,551        2,553  

Intangible amortization

     5,162        3,878  
  

 

 

    

 

 

 

ADJUSTED INCOME FROM OPERATIONS

   $ 45,694      $ 18,337  
  

 

 

    

 

 

 

REPLIGEN CORPORATION

RECONCILIATION OF GAAP NET INCOME TO NON-GAAP (ADJUSTED) NET INCOME

(Unaudited, amounts in thousands)

 

     Three Months Ended
March 31,
 
     2021     2020  

GAAP NET INCOME

   $ 29,450     $ 9,815  

ADJUSTMENTS TO NET INCOME:

    

Inventory step-up charges

     1,598       —    

Acquisition and integration costs

     2,551       2,553  

Intangible amortization

     5,162       3,878  

Loss on conversion of debt

     1       —    

Non-cash interest expense

     2,828       2,691  

Tax effect of non-GAAP charges

     (2,822     (2,177
  

 

 

   

 

 

 

ADJUSTED NET INCOME

   $ 38,768     $ 16,760  
  

 

 

   

 

 

 

 

8


REPLIGEN CORPORATION

RECONCILIATION OF GAAP NET INCOME PER SHARE TO

NON-GAAP (ADJUSTED) NET INCOME PER SHARE

(Unaudited)

 

     Three Months Ended
March 31,
 
     2021     2020  

GAAP NET INCOME PER SHARE—DILUTED

   $ 0.52     $ 0.18  

ADJUSTMENTS TO NET INCOME PER SHARE—DILUTED:

    

Inventory step-up charges

     0.03       —    

Acquisition and integration costs

     0.04       0.05  

Intangible amortization

     0.09       0.07  

Loss on conversion of debt

     —         —    

Non-cash interest expense

     0.05       0.05  

Tax effect of non-GAAP charges

     (0.05     (0.04
  

 

 

   

 

 

 

ADJUSTED NET INCOME PER SHARE—DILUTED

   $ 0.68     $ 0.32  
  

 

 

   

 

 

 

Totals may not add due to rounding.

    

REPLIGEN CORPORATION

RECONCILIATION OF GAAP NET INCOME TO ADJUSTED EBITDA

(Unaudited, amounts in thousands)

 

     Three Months Ended
March 31,
 
     2021     2020  

GAAP NET INCOME

   $ 29,450     $ 9,815  

ADJUSTMENTS:

    

Investment Income

     (52     (1,364

Interest Expense

     3,106       2,976  

Tax Provision

     3,655       861  

Depreciation

     3,255       2,485  

Amortization(1)

     5,189       3,905  
  

 

 

   

 

 

 

EBITDA

     44,603       18,678  

OTHER ADJUSTMENTS:

    

Inventory step-up charges

     1,598       —    

Acquisition and integration costs

     2,551       2,553  

Loss on conversion of debt

     1       —    
  

 

 

   

 

 

 

ADJUSTED EBITDA

   $ 48,753     $ 21,231  
  

 

 

   

 

 

 

 

(1)

Includes amortization of milestone payments in accordance with GAAP of $27 for each period presented.

 

9


REPLIGEN CORPORATION

RECONCILIATION OF GAAP COST OF SALES TO NON-GAAP (ADJUSTED) COST OF SALES

(Unaudited, amounts in thousands)

 

     Three Months Ended
March 31,
 
     2021     2020  

GAAP COST OF SALES

   $ 59,747     $ 31,982  

ADJUSTMENT TO COST OF SALES:

    

Inventory step-up charges

     (1,598     —    

Acquisition and integration costs

     (81     (280

Intangible amortization

     —         (127
  

 

 

   

 

 

 

ADJUSTED COST OF SALES

   $  58,068     $  31,575  
  

 

 

   

 

 

 

REPLIGEN CORPORATION

RECONCILIATION OF GAAP R&D EXPENSE TO NON-GAAP (ADJUSTED) R&D EXPENSE

(Unaudited, amounts in thousands)

 

     Three Months Ended
March 31,
 
     2021     2020  

GAAP R&D

   $ 7,612     $ 4,702  

ADJUSTMENT TO R&D:

    

Acquisition and integration costs

     (220     (282
  

 

 

   

 

 

 

ADJUSTED R&D

   $ 7,392     $ 4,420  
  

 

 

   

 

 

 

REPLIGEN CORPORATION

RECONCILIATION OF GAAP SG&A EXPENSE TO NON-GAAP (ADJUSTED) SG&A EXPENSE

(Unaudited, amounts in thousands)

 

     Three Months Ended
March 31,
 
     2021     2020  

GAAP SG&A EXPENSE

   $ 39,095     $ 27,500  

ADJUSTMENTS TO SG&A EXPENSE:

    

Acquisition and integration costs

     (2,250     (1,990

Intangible amortization

     (5,162     (3,751
  

 

 

   

 

 

 

ADJUSTED SG&A EXPENSE

   $ 31,683     $ 21,759  
  

 

 

   

 

 

 

 

10


REPLIGEN CORPORATION

RECONCILIATION OF GAAP NET INCOME GUIDANCE TO ADJUSTED (NON-GAAP NET INCOME GUIDANCE)

 

(in thousands)    Twelve months ending December 31, 2020  
     Low End     High End  

GUIDANCE ON NET INCOME

   $ 95,000     $ 99,000  

ADJUSTMENTS TO GUIDANCE ON NET INCOME:

    

Acquisition and integration costs

     6,517       6,517  

Inventory Step-Up Costs

     1,798       1,798  

Anticipated pre-tax amortization of acquisition-related intangible assets

     20,651       20,651  

Non-cash interest expense

     11,097       11,097  

Loss on conversion of debt

     1       1  

Tax effect of intangible amortization and integration

     (9,315     (9,315

Guidance rounding adjustment

     251       251  
  

 

 

   

 

 

 

GUIDANCE ON ADJUSTED NET INCOME

   $ 126,000     $ 130,000  
  

 

 

   

 

 

 

REPLIGEN CORPORATION

RECONCILIATION OF GAAP NET INCOME PER SHARE GUIDANCE TO

ADJUSTED (NON-GAAP) NET INCOME PER SHARE GUIDANCE

 

     Twelve months ending December 31, 2020  
     Low End     High End  

GUIDANCE ON NET INCOME PER SHARE—DILUTED

   $ 1.67     $ 1.74  

ADJUSTMENTS TO GUIDANCE ON NET INCOME PER SHARE—DILUTED:

     .    

Acquisition and integration costs

   $ 0.11     $ 0.11  

Inventory Step-Up Costs

   $ 0.03     $ 0.03  

Anticipated pre-tax amortization of acquisition-related intangible assets

   $ 0.36     $ 0.36  

Non-cash interest expense

   $ 0.19     $ 0.19  

Loss on conversion of debt

   $ 0.00     $ 0.00  

Tax effect of intangible amortization and integration

   ($ 0.16   ($ 0.16

Guidance rounding adjustment

   $ 0.00     $ 0.00  
  

 

 

   

 

 

 

GUIDANCE ON ADJUSTED NET INCOME PER SHARE—DILUTED

   $ 2.21     $ 2.28  
  

 

 

   

 

 

 

Totals may not add due to rounding.

    

# # #

 

11

EX-101.SCH 3 rgen-20210504.xsd XBRL TAXONOMY EXTENSION SCHEMA 100000 - Document - Document and Entity Information link:calculationLink link:presentationLink link:definitionLink EX-101.LAB 4 rgen-20210504_lab.xml XBRL TAXONOMY EXTENSION LABEL LINKBASE Cover [Abstract] Cover [Abstract] Entity Registrant Name Entity Registrant Name Amendment Flag Amendment Flag Entity Central Index Key Entity Central Index Key Document Type Document Type Document Period End Date Document Period End Date Entity Incorporation State Country Code Entity Incorporation State Country Code Entity File Number Entity File Number Entity Tax Identification Number Entity Tax Identification Number Entity Address, Address Line One Entity Address, Address Line One Entity Address, Address Line Two Entity Address, Address Line Two Entity Address, Address Line Three Entity Address, Address Line Three Entity Address, City or Town Entity Address, City or Town Entity Address, State or Province Entity Address, State or Province Entity Address, Postal Zip Code Entity Address, Postal Zip Code City Area Code City Area Code Local Phone Number Local Phone Number Written Communications Written Communications Soliciting Material Soliciting Material Pre Commencement Tender Offer Pre Commencement Tender Offer Pre Commencement Issuer Tender Offer Pre Commencement Issuer Tender Offer Security 12b Title Security 12b Title Trading Symbol Trading Symbol Security Exchange Name Security Exchange Name Entity Emerging Growth Company Entity Emerging Growth Company EX-101.PRE 5 rgen-20210504_pre.xml XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE GRAPHIC 6 g227347g0504042618057.jpg GRAPHIC begin 644 g227347g0504042618057.jpg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end XML 7 d227347d8k_htm.xml IDEA: XBRL DOCUMENT 0000730272 2021-05-04 2021-05-04 REPLIGEN CORP false 0000730272 8-K 2021-05-04 DE 001-14656 04-2729386 41 Seyon Street Bldg. 1 Suite 100 Waltham MA 02453 (781) 250-0111 false false false false Common Stock, par value $0.01 per share RGEN NASDAQ false XML 8 R1.htm IDEA: XBRL DOCUMENT v3.21.1
Document and Entity Information
May 04, 2021
Cover [Abstract]  
Entity Registrant Name REPLIGEN CORP
Amendment Flag false
Entity Central Index Key 0000730272
Document Type 8-K
Document Period End Date May 04, 2021
Entity Incorporation State Country Code DE
Entity File Number 001-14656
Entity Tax Identification Number 04-2729386
Entity Address, Address Line One 41 Seyon Street
Entity Address, Address Line Two Bldg. 1
Entity Address, Address Line Three Suite 100
Entity Address, City or Town Waltham
Entity Address, State or Province MA
Entity Address, Postal Zip Code 02453
City Area Code (781)
Local Phone Number 250-0111
Written Communications false
Soliciting Material false
Pre Commencement Tender Offer false
Pre Commencement Issuer Tender Offer false
Security 12b Title Common Stock, par value $0.01 per share
Trading Symbol RGEN
Security Exchange Name NASDAQ
Entity Emerging Growth Company false
EXCEL 9 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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end XML 10 Show.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 11 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 12 FilingSummary.xml IDEA: XBRL DOCUMENT 3.21.1 html 1 95 1 false 0 0 false 0 false false R1.htm 100000 - Document - Document and Entity Information Sheet http://www.repligencorp.com//20210504/taxonomy/role/DocumentDocumentAndEntityInformation Document and Entity Information Cover 1 false false All Reports Book All Reports d227347d8k.htm d227347dex991.htm rgen-20210504.xsd rgen-20210504_lab.xml rgen-20210504_pre.xml http://xbrl.sec.gov/dei/2019-01-31 true false JSON 15 MetaLinks.json IDEA: XBRL DOCUMENT { "instance": { "d227347d8k.htm": { "axisCustom": 0, "axisStandard": 0, "contextCount": 1, "dts": { "inline": { "local": [ "d227347d8k.htm" ] }, "labelLink": { "local": [ "rgen-20210504_lab.xml" ], "remote": [ "https://xbrl.sec.gov/dei/2019/dei-doc-2019-01-31.xml" ] }, "presentationLink": { "local": [ "rgen-20210504_pre.xml" ] }, "referenceLink": { "remote": [ "https://xbrl.sec.gov/dei/2019/dei-ref-2019-01-31.xml" ] }, "schema": { "local": [ "rgen-20210504.xsd" ], "remote": [ "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "http://www.xbrl.org/dtr/type/nonNumeric-2009-12-16.xsd", "http://www.xbrl.org/dtr/type/numeric-2009-12-16.xsd", "http://xbrl.sec.gov/sic/2011/sic-2011-01-31.xsd", "https://xbrl.sec.gov/naics/2017/naics-2017-01-31.xsd", "http://www.xbrl.org/lrr/role/deprecated-2009-12-16.xsd", "http://www.xbrl.org/2006/ref-2006-02-27.xsd" ] } }, "elementCount": 25, "entityCount": 1, "hidden": { "http://xbrl.sec.gov/dei/2019-01-31": 3, "total": 3 }, "keyCustom": 0, "keyStandard": 95, "memberCustom": 0, "memberStandard": 0, "nsprefix": "rgen", "nsuri": "http://www.repligencorp.com/20210504", "report": { "R1": { "firstAnchor": { "ancestors": [ "p", "div", "div", "body", "html" ], "baseRef": "d227347d8k.htm", "contextRef": "duration_2021-05-04_to_2021-05-04", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "document", "isDefault": "true", "longName": "100000 - Document - Document and Entity Information", "role": "http://www.repligencorp.com//20210504/taxonomy/role/DocumentDocumentAndEntityInformation", "shortName": "Document and Entity Information", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "p", "div", "div", "body", "html" ], "baseRef": "d227347d8k.htm", "contextRef": "duration_2021-05-04_to_2021-05-04", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } } }, "segmentCount": 0, "tag": { "dei_AmendmentFlag": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.", "label": "Amendment Flag", "terseLabel": "Amendment Flag" } } }, "localname": "AmendmentFlag", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.repligencorp.com//20210504/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_CityAreaCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Area code of city", "label": "City Area Code", "terseLabel": "City Area Code" } } }, "localname": "CityAreaCode", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.repligencorp.com//20210504/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_CoverAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Cover page.", "label": "Cover [Abstract]", "terseLabel": "Cover [Abstract]" } } }, "localname": "CoverAbstract", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "xbrltype": "stringItemType" }, "dei_DocumentPeriodEndDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The end date of the period reflected on the cover page if a periodic report. For all other reports and registration statements containing historical data, it is the date up through which that historical data is presented. If there is no historical data in the report, use the filing date. The format of the date is CCYY-MM-DD.", "label": "Document Period End Date", "terseLabel": "Document Period End Date" } } }, "localname": "DocumentPeriodEndDate", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.repligencorp.com//20210504/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "dateItemType" }, "dei_DocumentType": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.", "label": "Document Type", "terseLabel": "Document Type" } } }, "localname": "DocumentType", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.repligencorp.com//20210504/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "submissionTypeItemType" }, "dei_EntityAddressAddressLine1": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 1 such as Attn, Building Name, Street Name", "label": "Entity Address, Address Line One", "terseLabel": "Entity Address, Address Line One" } } }, "localname": "EntityAddressAddressLine1", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.repligencorp.com//20210504/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressAddressLine2": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 2 such as Street or Suite number", "label": "Entity Address, Address Line Two", "terseLabel": "Entity Address, Address Line Two" } } }, "localname": "EntityAddressAddressLine2", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.repligencorp.com//20210504/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressAddressLine3": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 3 such as an Office Park", "label": "Entity Address, Address Line Three", "terseLabel": "Entity Address, Address Line Three" } } }, "localname": "EntityAddressAddressLine3", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.repligencorp.com//20210504/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressCityOrTown": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the City or Town", "label": "Entity Address, City or Town", "terseLabel": "Entity Address, City or Town" } } }, "localname": "EntityAddressCityOrTown", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.repligencorp.com//20210504/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressPostalZipCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Code for the postal or zip code", "label": "Entity Address, Postal Zip Code", "terseLabel": "Entity Address, Postal Zip Code" } } }, "localname": "EntityAddressPostalZipCode", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.repligencorp.com//20210504/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressStateOrProvince": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the state or province.", "label": "Entity Address, State or Province", "terseLabel": "Entity Address, State or Province" } } }, "localname": "EntityAddressStateOrProvince", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.repligencorp.com//20210504/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "stateOrProvinceItemType" }, "dei_EntityCentralIndexKey": { "auth_ref": [ "r5" ], "lang": { "en-us": { "role": { "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.", "label": "Entity Central Index Key", "terseLabel": "Entity Central Index Key" } } }, "localname": "EntityCentralIndexKey", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.repligencorp.com//20210504/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "centralIndexKeyItemType" }, "dei_EntityEmergingGrowthCompany": { "auth_ref": [ "r5" ], "lang": { "en-us": { "role": { "documentation": "Indicate if registrant meets the emerging growth company criteria.", "label": "Entity Emerging Growth Company", "terseLabel": "Entity Emerging Growth Company" } } }, "localname": "EntityEmergingGrowthCompany", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.repligencorp.com//20210504/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_EntityFileNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.", "label": "Entity File Number", "terseLabel": "Entity File Number" } } }, "localname": "EntityFileNumber", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.repligencorp.com//20210504/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "fileNumberItemType" }, "dei_EntityIncorporationStateCountryCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Two-character EDGAR code representing the state or country of incorporation.", "label": "Entity Incorporation State Country Code", "terseLabel": "Entity Incorporation State Country Code" } } }, "localname": "EntityIncorporationStateCountryCode", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.repligencorp.com//20210504/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "edgarStateCountryItemType" }, "dei_EntityRegistrantName": { "auth_ref": [ "r5" ], "lang": { "en-us": { "role": { "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.", "label": "Entity Registrant Name", "terseLabel": "Entity Registrant Name" } } }, "localname": "EntityRegistrantName", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.repligencorp.com//20210504/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityTaxIdentificationNumber": { "auth_ref": [ "r5" ], "lang": { "en-us": { "role": { "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.", "label": "Entity Tax Identification Number", "terseLabel": "Entity Tax Identification Number" } } }, "localname": "EntityTaxIdentificationNumber", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.repligencorp.com//20210504/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "employerIdItemType" }, "dei_LocalPhoneNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Local phone number for entity.", "label": "Local Phone Number", "terseLabel": "Local Phone Number" } } }, "localname": "LocalPhoneNumber", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.repligencorp.com//20210504/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_PreCommencementIssuerTenderOffer": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.", "label": "Pre Commencement Issuer Tender Offer", "terseLabel": "Pre Commencement Issuer Tender Offer" } } }, "localname": "PreCommencementIssuerTenderOffer", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.repligencorp.com//20210504/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_PreCommencementTenderOffer": { "auth_ref": [ "r3" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.", "label": "Pre Commencement Tender Offer", "terseLabel": "Pre Commencement Tender Offer" } } }, "localname": "PreCommencementTenderOffer", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.repligencorp.com//20210504/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_Security12bTitle": { "auth_ref": [ "r0" ], "lang": { "en-us": { "role": { "documentation": "Title of a 12(b) registered security.", "label": "Security 12b Title", "terseLabel": "Security 12b Title" } } }, "localname": "Security12bTitle", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.repligencorp.com//20210504/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "securityTitleItemType" }, "dei_SecurityExchangeName": { "auth_ref": [ "r1" ], "lang": { "en-us": { "role": { "documentation": "Name of the Exchange on which a security is registered.", "label": "Security Exchange Name", "terseLabel": "Security Exchange Name" } } }, "localname": "SecurityExchangeName", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.repligencorp.com//20210504/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "edgarExchangeCodeItemType" }, "dei_SolicitingMaterial": { "auth_ref": [ "r4" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.", "label": "Soliciting Material", "terseLabel": "Soliciting Material" } } }, "localname": "SolicitingMaterial", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.repligencorp.com//20210504/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_TradingSymbol": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Trading symbol of an instrument as listed on an exchange.", "label": "Trading Symbol", "terseLabel": "Trading Symbol" } } }, "localname": "TradingSymbol", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.repligencorp.com//20210504/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "tradingSymbolItemType" }, "dei_WrittenCommunications": { "auth_ref": [ "r6" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.", "label": "Written Communications", "terseLabel": "Written Communications" } } }, "localname": "WrittenCommunications", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.repligencorp.com//20210504/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" } }, "unitCount": 0 } }, "std_ref": { "r0": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b" }, "r1": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "d1-1" }, "r2": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "13e", "Subsection": "4c" }, "r3": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "14d", "Subsection": "2b" }, "r4": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "14a", "Subsection": "12" }, "r5": { "Name": "Regulation 12B", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b-2" }, "r6": { "Name": "Securities Act", "Number": "230", "Publisher": "SEC", "Section": "425" } }, "version": "2.1" } ZIP 16 0001193125-21-149030-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001193125-21-149030-xbrl.zip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end